RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) Stock Price, Quote, News & History

Key Statistics

Open

Volume / Avg.

0 / 3.22K

Day Range

- - -

52 Wk Range

0.01 - 0.12

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

Recent Restart Life Sciences Corp News

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a treatment of Major Depressive Disorder (MDD).

Lara Goldstein

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

Lara Goldstein

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.

Lara Goldstein

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.

Lara Goldstein

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.

Lara Goldstein

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-556.04K

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

2.30M

Free Cash Flow (TTM)

-556.04K

Capital Expenditure (TTM)

Net Change in Cash (TTM)

899.22K

Valuation Metrics

Enterprise Value

$2.48M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

28.81

PB Ratio (TTM)

3.73

Earnings Yield % (TTM)

-21.33%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.02

Company Debt

Total Debt

$306.46K

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

Total Cash

$1.14M

Debt to Equity

0.23

Issuance of Debt (TTM)

Repayment of Debt (TTM)

Key Statistics

Open

Volume / Avg.

0 / 3.22K

Day Range

- - -

52 Wk Range

0.01 - 0.12

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

About

Sector

Health Care

Industry

Biotechnology

Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

NMLSF

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

NMLSF

FAQ

How do I buy RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) stock?

You can purchase shares of RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (OTCPK:NMLSF) through any online brokerage.

View our list of the best stock brokerages

Who are RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) competitors?

There are no as such competitors for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp..

What is the forecast, or price target, for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) stock?

There is no analysis for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. to provide a consensus price target.

What is the current price for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF)?

The stock price for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (OTCPK: NMLSF) is $0.06735 last updated August 11, 2026 at 3:09 PM EDT.

Does RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) pay a dividend?

There are no upcoming dividends for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp..

When is RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (OTCPK:NMLSF) reporting earnings?

RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. does not have any upcoming earnings scheduled.

Is RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) going to split?

There is no upcoming split for RESTART LIFE SCIENCES CP by Restart Life Sciences Corp..

What sector and industry does RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. (NMLSF) operate in?

RESTART LIFE SCIENCES CP by Restart Life Sciences Corp. is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.